Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain

Inclusion Criteria:

- Patient has advanced idiopathic Parkinson's Disease associated chronic pain assessed
by a Likert Pain Scale

- Patient is taking Levodopa with a stable daily dose of at least 200 mg for at least
21 days prior to start

- Hoehn and Yahr stage score of II to IV

- Mini-Mental State Examination (MMSE) score ≥ 25

- If an antidepressant drug is taken, the dose must be stable for at least 21 days

Exclusion Criteria:

- Therapy with a Dopamine Agonist within 21 days prior to start

- Discontinuation from previous Dopamine Agonist Therapy due to lack of efficacy

- Therapy with Dopamine-modulating substances 21 days prior to start

- Therapy with analgesics for the treatment for pain, unless the dose has been stable

- Chronic alcohol or drug abuse

- Medical or psychiatric condition that, in the opinion of the investigator, could
jeopardize or would compromise the patient's ability to participate in this study

- Hypersensitivity to any components of the Investigational Medicinal Product (IMP) or
comparative drugs

- Atypical Parkinson's Disease Syndrome due to drugs

- History of deep brain stimulation

- Significant skin disease that would make transdermal drug use inappropriate

- Electroconvulsive therapy within 12 weeks prior to start

- Evidence of an Impulse Control Disorder

- Previous diagnosis of severe Restless Legs Syndrome

- Chronic Migraine

- Severe Depression

- Symptomatic Orthostatic Hypotension